Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;7(8):607-12.
doi: 10.14740/jocmr2149w. Epub 2015 Jun 9.

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study

Masashi Ishikawa  1 , Masahiko Takai  1 , Hajime Maeda  1 , Akira Kanamori  1 , Akira Kubota  1 , Hikaru Amemiya  1 , Takashi Iizuka  1 , Kotaro Iemitsu  1 , Tomoyuki Iwasaki  1 , Goro Uehara  1 , Shinichi Umezawa  1 , Mitsuo Obana  1 , Hideaki Kaneshige  1 , Mizuki Kaneshiro  1 , Takehiro Kawata  1 , Nobuo Sasai  1 , Tatsuya Saito  1 , Tetsuo Takuma  1 , Hiroshi Takeda  1 , Keiji Tanaka  1 , Nobuaki Tsurui  1 , Shigeru Nakajima  1 , Kazuhiko Hoshino  1 , Shin Honda  1 , Hideo Machimura  1 , Kiyokazu Matoba  1 , Fuyuki Minagawa  1 , Nobuaki Minami  1 , Yukiko Miyairi  1 , Atsuko Mokubo  1 , Tetsuya Motomiya  1 , Manabu Waseda  1 , Masaaki Miyakawa  1 , Yoshikazu Naka  1 , Yasuo Terauchi  2 , Yasushi Tanaka  3 , Ikuro Matsuba  1
Affiliations

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study

Masashi Ishikawa et al. J Clin Med Res. 2015 Aug.

Abstract

Background: It is unclear whether dipeptidyl peptidase-4 inhibitors decrease hemoglobin A1c (HbA1c) in a glucose-dependent manner in patients on insulin therapy who have impaired insulin secretion. This study investigated factors influencing the efficacy of sitagliptin when used concomitantly with insulin to treat type 2 diabetes mellitus (T2DM) in the real-world setting.

Methods: A retrospective study was conducted of 1,004 T2DM patients at 36 Japanese clinics associated with the Diabetes Task Force of the Kanagawa Physicians Association. Eligible patients had been on insulin for at least 6 months, with a baseline HbA1c of 7.0% (53 mmol/mol) or higher. Baseline characteristics and laboratory data from 495 patients were subjected to multiple regression analysis to identify factors influencing the change of HbA1c.

Results: Most patients (n = 809) received sitagliptin at a dose of 50 mg. In the 1,004 patients, HbA1c decreased by 0.74% (6 mmol/mol) and body weight increased by 0.1 kg after 6 months of combination therapy. Multiple regression analysis showed that a higher baseline HbA1c, older age, and lower body mass index influenced the change of HbA1c after 6 months. Hypoglycemic symptoms occurred in 7.4%, but none were severe.

Conclusions: These results emphasize the importance of a higher HbA1c at the commencement of sitagliptin therapy in patients on insulin. Glucose-dependent suppression of glucagon secretion by sitagliptin may be useful in patients with impaired insulin secretion. Sitagliptin can be used concomitantly with insulin irrespective of the insulin regimen, duration of insulin treatment, and concomitant medications.

Keywords: Body weight; Combination therapy; HbA1c; Insulin; Multiple regression analysis; Sitagliptin; Type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in hemoglobin A1c, body weight, and insulin dose (n = 1,004). Data are the mean ± standard deviation. Analysis of variance vs. baseline. *P < 0.05. M: months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, Farrokhi F. et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–3435. doi: 10.2337/dc13-0277. - DOI - PMC - PubMed
    1. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J. 2013;60(6):733–742. doi: 10.1507/endocrj.EJ12-0293. - DOI - PubMed
    1. Shimoda S, Iwashita S, Ichimori S, Matsuo Y, Goto R, Maeda T, Matsuo T. et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J. 2013;60(10):1207–1214. doi: 10.1507/endocrj.EJ13-0198. - DOI - PubMed
    1. Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol Ther. 2013;15(3):237–240. doi: 10.1089/dia.2012.0214. - DOI - PubMed
    1. Kadowaki T, Tajima N, Odawara M, Minamide T, Kawashima M, Yanagida D, Okamoto T. et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int. 2013;4:160–172. doi: 10.1007/s13340-013-0109-z. - DOI

LinkOut - more resources